Skip to content

Total Assets at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.39B+86.6%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$1.61B+41.8%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$497.6M+64.7%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$1.46B+205%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$244.66M+9.2%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$393.48M

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,335%
Enterprise value$630.81M-940%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's total assets?
Alto Neuroscience (ANRO) reported total assets of $276.26M in Q1 2026.
How has Alto Neuroscience's total assets changed year-over-year?
Alto Neuroscience's total assets increased by 60.7% year-over-year, from $171.92M to $276.26M.
What is the long-term trend for Alto Neuroscience's total assets?
Over 2 years (2023 to 2025), Alto Neuroscience's total assets has grown at a 46.0% compound annual growth rate (CAGR), from $86.63M to $184.69M.
What does total assets mean?
The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.